A Trial to Evaluate Safety and Tolerability of SHR-1316 in Cancer Patients

Summary

In many types of human tumors, PD-L1 is highly expressed. Such high expression has often been associated with poor prognosis in cancer patients. SHR-1316 is a humanized IgG4 monoclonal antibody that binds specifically to human PD-L1.

Timeline

Start

2017-06-01

Primary completion

2019-04-09

Completion

2019-07-05

Drugs

Indications